(Q36491065)

English

Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir (English)

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

Eric S Furfine

1

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Christopher T Baker

2

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Michael R Hale

3

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

David J Reynolds

4

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Jo A Salisbury

5

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Andy D Searle

6

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Scott D Studenberg

7

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Dan Todd

8

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Roger D Tung

9

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Andrew Spaltenstein

10

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

language of work or name

0 references

publication date

1 March 2004

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Antimicrobial Agents and Chemotherapy

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

48

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

3

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

791-798

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Clinical pharmacology and pharmacokinetics of amprenavir.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=353103

30 September 2017

A systematic review of the associations between dose regimens and medication compliance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=353103

30 September 2017

Strategies for optimizing adherence to highly active antiretroviral therapy: lessons from research and clinical practice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=353103

30 September 2017

Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=353103

30 September 2017

Adherence to protease inhibitor therapy and outcomes in patients with HIV infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=353103

30 September 2017

Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=353103

30 September 2017

The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=353103

30 September 2017

Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=353103

30 September 2017

Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=353103

30 September 2017

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=353103

30 September 2017

Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=353103

30 September 2017

Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=353103

30 September 2017

Randomized, double-blind comparison of two nelfinavir doses plus nucleosides in HIV-infected patients (Agouron study 511).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=353103

28 June 2018

Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=353103

28 June 2018

Effects of early antiretroviral treatment on HIV-1 RNA in blood and lymphoid tissue: a randomized trial of double versus triple therapy. Swiss HIV Cohort Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=353103

28 June 2018

A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. Amprenavir PROAB2002 Study Team.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=353103

28 June 2018

Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=353103

28 June 2018

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=353103

21 September 2018

3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=353103

21 September 2018

Adherence of human immunodeficiency virus-infected patients to antiretroviral therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=353103

21 September 2018

Improved survival among HIV-infected individuals following initiation of antiretroviral therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=353103

21 September 2018

Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults

1 reference

https://pubmed.ncbi.nlm.nih.gov/14982766

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen

1 reference

https://pubmed.ncbi.nlm.nih.gov/14982766

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of adherence on duration of virological suppression among patients receiving combination antiretroviral therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/14982766

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Update: trends in AIDS incidence -- United States, 1996

1 reference

https://pubmed.ncbi.nlm.nih.gov/14982766

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adherence to triple therapy and viral load response

1 reference

https://pubmed.ncbi.nlm.nih.gov/14982766

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1128/AAC.48.3.791-798.2004

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36491065&oldid=1635348773"